A conservative 3% trend means a $100 billion Medicare Advantage book could face a $3 billion shortfall. Even before the Final ...
In today’s Pharma Pulse, UK regulators seize thousands of fake weight loss pens, while new data reveals that the "miracle jab" is financially out of reach for nearly 70% of users.
In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while ...
In today’s Pharma Pulse, Eli Lilly launches the monthly Zepbound KwikPen to streamline obesity care, while Gilead Sciences moves to acquires Arcellx in a massive expansion of its cell therapy ...
In today’s Pharma Pulse, BioNTech escalates its patent battle against Moderna over next-gen COVID shots, while a new ...
In the first part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, explains how third ...
In today’s Pharma Pulse, Johnson & Johnson commits over $1 billion to a new biomanufacturing site in Pennsylvania, while Hims ...
The pharmaceutical industry now emphasizes gross-to-net revenue, driven by specialty drugs and rare-disease therapies, rather than market share. Pharmacy benefit managers (PBMs) significantly impact ...
In a recent discussion, John Stanford, executive director at Incubate,reacted to the Centers for Medicare & Medicaid Services’ (CMS) decision to expand Medicare drug price negot ...
A policy change allowing approval of some new drugs based on one adequate and well-controlled study could accelerate ...
A one-pen-per-month format could reduce total injector units required per treated patient, easing device-component constraints that have limited GLP-1 category supply scalability. Consolidation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results